Cargando…

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection

Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is incidentally given to kidney transplant recipients as tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Zwan, Marieke, Clahsen-Van Groningen, Marian C., van den Hoogen, Martijn W. F., Kho, Marcia M. L., Roodnat, Joke I., Mauff, Katya A. L., Roelen, Dave L., van Agteren, Madelon, Baan, Carla C., Hesselink, Dennis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350932/ https://www.ncbi.nlm.nih.gov/pubmed/32719676 http://dx.doi.org/10.3389/fimmu.2020.01332

Ejemplares similares

The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy
por: van der Zwan, Marieke, et al.
Publicado: (2018)

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection
por: van Vugt, Lukas K., et al.
Publicado: (2023)

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection
por: Hullegie‐Peelen, Daphne M., et al.
Publicado: (2022)

Oxalate deposition in renal allograft biopsies within 3 months after transplantation is associated with allograft dysfunction
por: Snijders, Malou L. H., et al.
Publicado: (2019)

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
por: van der Zwan, Marieke, et al.
Publicado: (2017)

Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
por: Sablik, Kasia A., et al.
Publicado: (2019)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection
por: van Besouw, Nicole M., et al.
Publicado: (2019)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis
por: de Weerd, Annelies, et al.
Publicado: (2014)

Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2021)

Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection
por: Sablik, Kasia A., et al.
Publicado: (2018)

Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2023)

The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease
por: Ali, Robert, et al.
Publicado: (2017)

Serum sickness following rabbit anti-thymocyte globulin for acute vascular renal allograft rejection
por: Teng, Jessie, et al.
Publicado: (2012)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Mast Cells in Kidney Transplant Biopsies With Borderline T Cell-mediated Rejection and Their Relation to Chronicity
por: Varol, Hilal, et al.
Publicado: (2023)

Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study
por: Verhoeven, Jeroen G. H. P., et al.
Publicado: (2021)

Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients
por: Niu, Qian, et al.
Publicado: (2020)

Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy
por: Ko, Eun Jeong, et al.
Publicado: (2019)

Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation
por: Betjes, Michiel G. H., et al.
Publicado: (2022)

Natural Antibodies and Alloreactive T Cells Long after Kidney Transplantation
por: van Besouw, Nicole M., et al.
Publicado: (2021)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation
por: Lee, Jae Geun, et al.
Publicado: (2016)

Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models
por: Mashima, Kiyomi, et al.
Publicado: (2021)

Costimulation Blockade in Kidney Transplant Recipients
por: van der Zwan, Marieke, et al.
Publicado: (2019)

Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection
por: Sablik, Kasia A., et al.
Publicado: (2020)

Alternative Living Kidney Donation Programs Boost Genetically Unrelated Donation
por: Poldervaart, Rosalie A., et al.
Publicado: (2015)

Anti-thymocyte globulin in haematology: Recent developments
por: Siddiqui, Salahuddin, et al.
Publicado: (2019)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro
por: Binder, Christian, et al.
Publicado: (2020)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection
por: van den Bosch, Thierry P. P., et al.
Publicado: (2017)

A Successful Approach to Kidney Transplantation in Patients With Enteric (Secondary) Hyperoxaluria
por: Roodnat, Joke I., et al.
Publicado: (2017)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
por: Tjon, Jennifer M.-L., et al.
Publicado: (2021)

Anti-Thymocyte Globulin Induced Acute Lung Injury in a Case of Renal Allograft Recipient
por: Gupta, Nimish, et al.
Publicado: (2021)

Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation
por: Chiu, Yu-Hsiang, et al.
Publicado: (2023)

Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_mcnb3s06gg2cq5un05do12dlit